Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens
Current Oncology · 2024
DOI: 10.3390/curroncol31060236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Leslie Hesnard und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Ovarian Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ovarian Cancer Canada-IRICoR, IRICoR.
Abstract (Originalsprache)
Epithelial ovarian cancer (EOC) has not significantly benefited from advances in immunotherapy, mainly because of the lack of well-defined actionable antigen targets. Using proteogenomic analyses of primary EOC tumors, we previously identified 91 aberrantly expressed tumor-specific antigens (TSAs) originating from unmutated genomic sequences. Most of these TSAs derive from non-exonic regions, and their expression results from cancer-specific epigenetic changes. The present study aimed to evaluate the immunogenicity of 48 TSAs selected according to two criteria: presentation by highly prevalent HLA allotypes and expression in a significant fraction of EOC tumors. Using targeted mass spectrometry analyses, we found that pulsing with synthetic TSA peptides leads to a high-level presentation on dendritic cells. TSA abundance correlated with the predicted binding affinity to the HLA allotype. We stimulated naïve CD8 T cells from healthy blood donors with TSA-pulsed dendritic cells and assessed their expansion with two assays: MHC-peptide tetramer staining and TCR Vβ CDR3 sequencing. We report that these TSAs can expand sizeable populations of CD8 T cells and, therefore, represent attractive targets for EOC immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, QC H3T 1J4, Canada.
- Department of Chemistry, University of Montreal, Montreal, QC H2V 0B3, Canada.
- Department of Medicine, University of Montreal, Montreal, QC H3C 3J7, Canada.
ORCID-Profile: Leslie Hesnard, Maxime Cahuzac, Chantal Durette, Krystel Vincent, Marie-Pierre Hardy, Joël Lanoix, Claude Perreault
Förderung
- Ovarian Cancer Canada-IRICoR
- IRICoR
Zitieren
APA
Hesnard, L., Thériault, C., Cahuzac, M., Durette, C., Vincent, K., Hardy, M. P., Lanoix, J., Lavallée, G. O., Humeau, J., Thibault, P., & Perreault, C. (2024). Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens. Current Oncology. https://doi.org/10.3390/curroncol31060236
Vancouver
Hesnard L, Thériault C, Cahuzac M, Durette C, Vincent K, Hardy MP, et al. Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens. Current Oncology. 2024. doi:10.3390/curroncol31060236
BibTeX
@article{Hesnard2024,
author = {Hesnard, Leslie and Thériault, Catherine and Cahuzac, Maxime and Durette, Chantal and Vincent, Krystel and Hardy, Marie-Pierre and Lanoix, Joël and Lavallée, Gabriel Ouellet and Humeau, Juliette and Thibault, Pierre and Perreault, Claude},
title = {Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31060236}
}
EUVIMED